Does the media favor IOVA or PCVX?

In the previous week, Vaxcyte had 12 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 16 mentions for Vaxcyte and 4 mentions for Iovance Biotherapeutics. Vaxcyte's average media sentiment score of 0.78 beat Iovance Biotherapeutics' score of 0.68 indicating that Vaxcyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaxcyte 9 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IOVA or KYMR?

In the previous week, Iovance Biotherapeutics and Iovance Biotherapeutics both had 4 articles in the media. Kymera Therapeutics' average media sentiment score of 1.71 beat Iovance Biotherapeutics' score of 0.68 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to IMVT or IOVA?

In the previous week, Iovance Biotherapeutics had 3 more articles in the media than Immunovant. MarketBeat recorded 4 mentions for Iovance Biotherapeutics and 1 mentions for Immunovant. Immunovant's average media sentiment score of 1.42 beat Iovance Biotherapeutics' score of 0.68 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IOVA or LNTH?

In the previous week, Iovance Biotherapeutics had 1 more articles in the media than Lantheus. MarketBeat recorded 4 mentions for Iovance Biotherapeutics and 3 mentions for Lantheus. Iovance Biotherapeutics' average media sentiment score of 0.68 beat Lantheus' score of 0.00 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to IOVA or LEGN?

In the previous week, Legend Biotech had 4 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 8 mentions for Legend Biotech and 4 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 0.68 beat Legend Biotech's score of 0.14 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Iovance Biotherapeutics (IOVA) Competitors

$3.91 +0.00 (+0.03%)

Closing price 06/18/2026 03:59 PM Eastern

Extended Trading

$3.92 +0.01 (+0.18%)

As of 06/18/2026 07:56 PM Eastern

Compare

IOVA vs. PCVX, KYMR, IMVT, LNTH, and LEGN

Should you buy Iovance Biotherapeutics stock or one of its competitors? MarketBeat compares Iovance Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Iovance Biotherapeutics include Vaxcyte (PCVX), Kymera Therapeutics (KYMR), Immunovant (IMVT), Lantheus (LNTH), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.

How does Iovance Biotherapeutics compare to Vaxcyte?

Iovance Biotherapeutics (NASDAQ:IOVA) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Iovance Biotherapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market. Comparatively, Vaxcyte has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

Vaxcyte has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Vaxcyte's return on equity of -32.51% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
Vaxcyte	N/A	-32.51%	-29.51%

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 3.3% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Iovance Biotherapeutics has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	6.63	-$390.98M	-$0.95	N/A
Vaxcyte	N/A	N/A	-$766.63M	-$6.88	N/A

In the previous week, Vaxcyte had 12 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 16 mentions for Vaxcyte and 4 mentions for Iovance Biotherapeutics. Vaxcyte's average media sentiment score of 0.78 beat Iovance Biotherapeutics' score of 0.68 indicating that Vaxcyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaxcyte	9 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Iovance Biotherapeutics presently has a consensus price target of $8.43, indicating a potential upside of 115.51%. Vaxcyte has a consensus price target of $86.00, indicating a potential upside of 67.19%. Given Iovance Biotherapeutics' higher possible upside, research analysts clearly believe Iovance Biotherapeutics is more favorable than Vaxcyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Vaxcyte	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Summary

Vaxcyte beats Iovance Biotherapeutics on 9 of the 15 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Kymera Therapeutics?

Iovance Biotherapeutics (NASDAQ:IOVA) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, media sentiment, analyst recommendations, dividends, earnings, institutional ownership and profitability.

Iovance Biotherapeutics has a beta of 0.74, suggesting that its share price is 26% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market.

Kymera Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	6.63	-$390.98M	-$0.95	N/A
Kymera Therapeutics	$39.21M	189.72	-$311.35M	-$3.57	N/A

77.0% of Iovance Biotherapeutics shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Iovance Biotherapeutics and Iovance Biotherapeutics both had 4 articles in the media. Kymera Therapeutics' average media sentiment score of 1.71 beat Iovance Biotherapeutics' score of 0.68 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Iovance Biotherapeutics presently has a consensus price target of $8.43, indicating a potential upside of 115.51%. Kymera Therapeutics has a consensus price target of $117.14, indicating a potential upside of 29.53%. Given Iovance Biotherapeutics' higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

Iovance Biotherapeutics has a net margin of -123.92% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Summary

Kymera Therapeutics beats Iovance Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 1.8% of Immunovant shares are owned by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Iovance Biotherapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Iovance Biotherapeutics	$263.50M	6.63	-$390.98M	-$0.95	N/A

In the previous week, Iovance Biotherapeutics had 3 more articles in the media than Immunovant. MarketBeat recorded 4 mentions for Iovance Biotherapeutics and 1 mentions for Immunovant. Immunovant's average media sentiment score of 1.42 beat Iovance Biotherapeutics' score of 0.68 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

Immunovant currently has a consensus price target of $37.33, suggesting a potential upside of 5.64%. Iovance Biotherapeutics has a consensus price target of $8.43, suggesting a potential upside of 115.51%. Given Iovance Biotherapeutics' higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Immunovant has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Iovance Biotherapeutics' return on equity of -50.17% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Summary

Iovance Biotherapeutics beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Lantheus?

Iovance Biotherapeutics (NASDAQ:IOVA) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Lantheus has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	6.63	-$390.98M	-$0.95	N/A
Lantheus	$1.54B	4.39	$233.56M	$4.15	25.04

Iovance Biotherapeutics has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its share price is 103% less volatile than the broader market.

Iovance Biotherapeutics currently has a consensus target price of $8.43, suggesting a potential upside of 115.51%. Lantheus has a consensus target price of $101.86, suggesting a potential downside of 1.98%. Given Iovance Biotherapeutics' higher probable upside, equities research analysts clearly believe Iovance Biotherapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Iovance Biotherapeutics had 1 more articles in the media than Lantheus. MarketBeat recorded 4 mentions for Iovance Biotherapeutics and 3 mentions for Lantheus. Iovance Biotherapeutics' average media sentiment score of 0.68 beat Lantheus' score of 0.00 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lantheus has a net margin of 18.05% compared to Iovance Biotherapeutics' net margin of -123.92%. Lantheus' return on equity of 29.32% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
Lantheus	18.05%	29.32%	15.00%

Summary

Lantheus beats Iovance Biotherapeutics on 10 of the 16 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Legend Biotech?

Iovance Biotherapeutics (NASDAQ:IOVA) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Iovance Biotherapeutics presently has a consensus price target of $8.43, indicating a potential upside of 115.51%. Legend Biotech has a consensus price target of $60.23, indicating a potential upside of 115.65%. Given Legend Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Legend Biotech is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Legend Biotech has higher revenue and earnings than Iovance Biotherapeutics. Legend Biotech is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	6.63	-$390.98M	-$0.95	N/A
Legend Biotech	$1.03B	5.04	-$296.80M	-$0.68	N/A

In the previous week, Legend Biotech had 4 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 8 mentions for Legend Biotech and 4 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 0.68 beat Legend Biotech's score of 0.14 indicating that Iovance Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

77.0% of Iovance Biotherapeutics shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 7.8% of Iovance Biotherapeutics shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Legend Biotech has a net margin of -21.98% compared to Iovance Biotherapeutics' net margin of -123.92%. Legend Biotech's return on equity of -24.92% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
Legend Biotech	-21.98%	-24.92%	-14.87%

Iovance Biotherapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market.

Summary

Legend Biotech beats Iovance Biotherapeutics on 10 of the 16 factors compared between the two stocks.

Get Iovance Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IOVA vs. The Competition

Export

Metric	Iovance Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.75B	$3.41B	$6.42B	$12.59B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-4.12	19.73	24.78	24.44
Price / Sales	6.63	329.79	554.03	122.85
Price / Cash	N/A	127.84	45.07	55.09
Price / Book	2.22	8.16	10.80	6.58
Net Income	-$390.98M	$23.94M	$3.57B	$337.17M
7 Day Performance	-4.14%	2.57%	0.72%	0.83%
1 Month Performance	5.70%	0.69%	0.41%	2.25%
1 Year Performance	97.53%	55.09%	29.34%	36.14%

Iovance Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IOVA Iovance Biotherapeutics	2.4861 of 5 stars	$3.91 +0.0%	$8.43 +115.5%	+97.5%	$1.75B	$263.50M	N/A	500
PCVX Vaxcyte	2.7232 of 5 stars	$49.56 +4.4%	$86.00 +73.5%	+56.5%	$7.16B	N/A	N/A	160	News Coverage Insider Trade
KYMR Kymera Therapeutics	2.4541 of 5 stars	$85.59 -0.7%	$117.14 +36.9%	+97.1%	$7.04B	$39.21M	N/A	170
IMVT Immunovant	2.2472 of 5 stars	$33.44 -0.5%	$37.33 +11.6%	+123.7%	$6.87B	N/A	N/A	120	Positive News
LNTH Lantheus	2.4708 of 5 stars	$104.67 +0.1%	$101.86 -2.7%	+31.2%	$6.82B	$1.54B	25.22	1,193	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IOVA) was last updated on 6/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. PCVX, KYMR, IMVT, LNTH, and LEGN

How does Iovance Biotherapeutics compare to Vaxcyte?

Summary

How does Iovance Biotherapeutics compare to Kymera Therapeutics?

Summary

How does Iovance Biotherapeutics compare to Immunovant?

Summary

How does Iovance Biotherapeutics compare to Lantheus?

Summary

How does Iovance Biotherapeutics compare to Legend Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. PCVX, KYMR, IMVT, LNTH, and LEGN

How does Iovance Biotherapeutics compare to Vaxcyte?

Which has more risk & volatility, IOVA or PCVX?

Is IOVA or PCVX more profitable?

Do institutionals and insiders hold more shares of IOVA or PCVX?

Which has higher valuation and earnings, IOVA or PCVX?

Does the media favor IOVA or PCVX?

Do analysts prefer IOVA or PCVX?

Summary

How does Iovance Biotherapeutics compare to Kymera Therapeutics?

Which has more volatility and risk, IOVA or KYMR?

Which has stronger valuation & earnings, IOVA or KYMR?

Do insiders & institutionals hold more shares of IOVA or KYMR?

Does the media refer more to IOVA or KYMR?

Do analysts prefer IOVA or KYMR?

Is IOVA or KYMR more profitable?

Summary

How does Iovance Biotherapeutics compare to Immunovant?

Do institutionals & insiders have more ownership in IMVT or IOVA?

Which has higher valuation & earnings, IMVT or IOVA?

Does the media refer more to IMVT or IOVA?

Which has more volatility & risk, IMVT or IOVA?

Do analysts prefer IMVT or IOVA?

Is IMVT or IOVA more profitable?

Summary

How does Iovance Biotherapeutics compare to Lantheus?

Which has preferable valuation and earnings, IOVA or LNTH?

Which has more volatility & risk, IOVA or LNTH?

Do analysts recommend IOVA or LNTH?

Does the media refer more to IOVA or LNTH?

Do institutionals and insiders hold more shares of IOVA or LNTH?

Is IOVA or LNTH more profitable?

Summary

How does Iovance Biotherapeutics compare to Legend Biotech?

Do analysts recommend IOVA or LEGN?

Which has stronger earnings & valuation, IOVA or LEGN?

Does the media refer more to IOVA or LEGN?

Do institutionals & insiders hold more shares of IOVA or LEGN?

Is IOVA or LEGN more profitable?

Which has more volatility and risk, IOVA or LEGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools